The Procter & Gamble Company (PG) 10-Q 18 Oct 23 2024 Q1 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION	3 Months Ended
	Sep. 30, 2023 shares
Entity Information [Line Items]
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Central Index Key	0000080424
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	OH
Entity File Number	1-434
Entity Tax Identification Number	31-0411980
Entity Address, Address Line One	One Procter & Gamble Plaza
Entity Address, City or Town	Cincinnati
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45202
City Area Code	513
Local Phone Number	983-1100
Document Transition Report	false
Document Quarterly Report	true
Document Type	10-Q
Document Period End Date	Sep. 30, 2023
Entity Registrant Name	PROCTER & GAMBLE CO
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	2,356,886,211
Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, without Par Value
Trading Symbol	PG
1.125% due 2023 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2023
Trading Symbol	PG23A
Security Exchange Name	NYSE
0.500% due 2024 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.500% Notes due 2024
Trading Symbol	PG24A
Security Exchange Name	NYSE
0.625% due 2024 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.625% Notes due 2024
Trading Symbol	PG24B
Security Exchange Name	NYSE
1.375% due 2025 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.375% Notes due 2025
Trading Symbol	PG25
Security Exchange Name	NYSE
0.110 due 2026 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.110% Notes due 2026
Trading Symbol	PG26D
Security Exchange Name	NYSE
3.250% EUR Notes due 2026 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	3.250% EUR Notes due 2026
Trading Symbol	PG26E
Security Exchange Name	NYSE
4.875% EUR due May 2027 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	4.875% EUR notes due May 2027
Trading Symbol	PG27A
Security Exchange Name	NYSE
1.200% due 2028 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.200% Notes due 2028
Trading Symbol	PG28
Security Exchange Name	NYSE
1.250% due 2029 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.250% Notes due 2029
Trading Symbol	PG29B
Security Exchange Name	NYSE
1.800% due 2029 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.800% Notes due 2029
Trading Symbol	PG29A
Security Exchange Name	NYSE
6.250% GBP due January 2030 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	6.250% GBP notes due January 2030
Trading Symbol	PG30
Security Exchange Name	NYSE
0.350% due 2030 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.350% Notes due 2030
Trading Symbol	PG30C
Security Exchange Name	NYSE
0.230% due 2031 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.230% Notes due 2031
Trading Symbol	PG31A
Security Exchange Name	NYSE
3.250% EUR Notes Due 2031 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	3.250% EUR Notes due 2031
Trading Symbol	PG31B
Security Exchange Name	NYSE
5.250% GBP due January 2033 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	5.250% GBP notes due January 2033
Trading Symbol	PG33
Security Exchange Name	NYSE
1.875% due 2038 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2038
Trading Symbol	PG38
Security Exchange Name	NYSE
0.900% due 2041 [Domain]
Entity Information [Line Items]
Title of 12(b) Security	0.900% Notes due 2041
Trading Symbol	PG41
Security Exchange Name	NYSE
NEW YORK STOCK EXCHANGE, INC. [Member] | Common Stock [Member]
Entity Information [Line Items]
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Net Sales		$ 21,871	$ 20,612
Cost of Products Sold		10,501	10,846
Selling, General and Administrative Expense		5,604	4,827
Operating Income		5,767	4,939
Interest Expense		(225)	(123)
Interest Income		128	42
Other Non-operating Income/(Loss), Net		132	139
Earnings/(Loss) from Continuing Operations Before Income Taxes		5,802	4,997
Income Taxes on Continuing Operations		1,246	1,034
Net Earnings		4,556	3,963
Net Income (Loss) Attributable to Noncontrolling Interest		35	24
Net Income (Loss) Attributable to Parent		$ 4,521	$ 3,939
Basic Net Earnings Per Common Share
Basic Net Earnings/(Loss) Per Common Share	[1],[2]	$ 1.89	$ 1.62
Diluted Net Earnings Per Common Share
Diluted Net Earnings/(Loss) Per Common Share	[1],[2]	$ 1.83	$ 1.57
[1]Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.[2]Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

CONDOLIDATED STATEMENTS OF COMP

CONDOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Earnings	$ 4,556	$ 3,963
Foreign Currency Translation	(409)	(712)
Unrealized Gains/(Losses) on Investment Securities	(1)	(2)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	45	87
Total Other Comprehensive Income (Loss), Net of Tax	(366)	(627)
Total Comprehensive Income/(Loss)	4,190	3,336
Less: Total Comprehensive Income Attributable to Noncontrolling Interest	33	19
Total Comprehensive Income/(Loss) Attributable to Procter & Gamble	$ 4,157	$ 3,317

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) shares in Millions, $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Current Assets
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 9,733	$ 8,246
Accounts Receivable	6,215	5,471
Inventories
Materials and Supplies	1,759	1,863
Work in Process	972	956
Finished Goods	4,386	4,254
Total Inventories	7,117	7,073
Prepaid Expenses and Other Current Assets	1,875	1,858
Total Current Assets	24,940	22,648
Property, Plant and Equipment, Net	21,636	21,909
Goodwill	40,239	40,659
Trademarks and Other Intangible Assets, Net	23,637	23,783
Other Noncurrent Assets	12,079	11,830
Total Assets	122,531	120,829
Current Liabilities
Accounts Payable	14,435	14,598
Accrued and Other Liabilities	10,912	10,929
Debt Due Within One Year	11,811	10,229
Total Current Liabilities	37,158	35,756
Long-Term Debt	24,069	24,378
Deferred Income Tax Liabilities, Net	6,814	6,478
Other Noncurrent Liabilities	6,477	7,152
Total Liabilities	74,517	73,764
Shareholders' Equity
Preferred Stock	$ 812	$ 819
Common Stock, Shares, Issued	4,009.2	4,009.2
Common Stock, Value, Issued	$ 4,009	$ 4,009
Additional Paid in Capital	66,822	66,556
Reserve For ESOP Debt Retirement	(782)	(821)
Accumulated Other Comprehensive Income/(Loss)	(12,583)	(12,220)
Treasury Stock	(131,029)	(129,736)
Retained Earnings	120,443	118,170
Noncontrolling Interest	321	288
Total Shareholders' Equity	48,014	47,065
Total Liabilities and Shareholders' Equity	$ 122,531	$ 120,829

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Reserve for ESOP Debt Retirement [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common	Retained Earnings [Member]	Noncontrolling Interest [Member]
Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2022		2,393,877
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2022	$ 46,854	$ 4,009	$ 843	$ 65,795	$ (916)	$ (12,189)	$ (123,382)	$ 112,429	$ 265
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Earnings	3,963							3,939	24
Other Comprehensive Income (Loss), Net of Tax	$ (627)					(622)			(5)
Common Stock, Dividends, Per Share, Cash Paid	$ 0.9133
Dividends, Common Stock	$ (2,189)							(2,189)
Dividends, Preferred Stock	(71)							(71)
Stock Repurchased During Period, Shares		(28,189)
Stock Repurchased During Period, Value	(4,000)						(4,000)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		3,011
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	328			159			169
Stock Issued During Period, Shares, Conversion of Convertible Securities		998
Stock Issued During Period, Value, Conversion of Convertible Securities	0		9	1			8
ESOP Debt Impacts	101				46			55
Noncontrolling Interest, Period Increase (Decrease)	(25)			0					(25)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022		2,369,697
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2022	44,334	$ 4,009	834	65,955	(870)	(12,811)	(127,205)	114,163	259
Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2023		2,362,120
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2023	47,065	$ 4,009	819	66,556	(821)	(12,220)	(129,736)	118,170	288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Earnings	4,556							4,521	35
Other Comprehensive Income (Loss), Net of Tax	$ (366)					(363)			(2)
Common Stock, Dividends, Per Share, Cash Paid	$ 0.9407
Dividends, Common Stock	$ (2,225)							(2,225)
Dividends, Preferred Stock	(70)							(70)
Stock Repurchased During Period, Shares		(9,843)
Stock Repurchased During Period, Value	(1,508)						(1,508)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		3,721
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	474			265			209
Stock Issued During Period, Shares, Conversion of Convertible Securities		888
Stock Issued During Period, Value, Conversion of Convertible Securities	0		7	1			6
ESOP Debt Impacts	87				39			48
Noncontrolling Interest, Period Increase (Decrease)	0			0					0
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023		2,356,886
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2023	$ 48,014	$ 4,009	$ 812	$ 66,822	$ (782)	$ (12,583)	$ (131,029)	$ 120,443	$ 321

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Statement of Cash Flows [Abstract]
Cash, Cash Equivalent and Restricted Cash Beginning of Period	$ 8,246	$ 7,214
Operating Activities
Net Earnings	4,556	3,963
Depreciation and Amortization	702	663
Share-based Compensation Expense	125	105
Deferred Income Taxes	102	(130)
Gain (Loss) on Disposition of Assets	(3)	(1)
Changes In:
Accounts Receivable	(830)	(740)
Inventories	(142)	(893)
Accounts Payable, Accrued and Other Liabilities	857	1,495
Other Operating Assets and Liabilities	(671)	(454)
Other Noncash Expense	208	62
Total Operating Activities	4,904	4,070
Investing Activities
Payments to Acquire Property, Plant, and Equipment	(925)	(890)
Proceeds from Asset Sales	3	5
Payments for (Proceeds from) Businesses and Interest in Affiliates	0	(2)
Payments for (Proceeds from) Investments	(300)	55
Total Investing Activites	(1,222)	(832)
Financing Activities
Dividends to Shareholders	(2,290)	(2,255)
Proceeds from Short-term Debt, Maturing in More than Three Months	2,179	2,975
Repayments of Short-term Debt, Maturing in More than Three Months	(1,906)	(265)
Change in Short-term Debt	2,172	1,727
Repayments of Long-term Debt	(1,004)	(1,877)
Treasury Stock Purchases	(1,500)	(4,000)
Impact of Stock Options and Other	312	188
Total Financing Activities	(2,038)	(3,507)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(156)	(235)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total	1,487	(504)
Cash, Cash Equivalents and Restricted Cash, End of Period	$ 9,733	$ 6,710

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Basis of PresentationThe accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble," "P&G," "we" or "our") should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023. We have prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.

NEW ACCOUNTING PRONOUNCEMENTS A

NEW ACCOUNTING PRONOUNCEMENTS AND POLICIES	3 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Update and Change in Accounting Principle	New Accounting Pronouncements and Policies In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". This guidance requires annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. This ASU was effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. We adopted this ASU effective July 1, 2023, except for the amendment on rollforward information, which will be adopted July 1, 2024. See Note 10, Supplier Finance Programs, for the disclosure. No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial Statements.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Segment Information Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and 5) Baby, Feminine & Family Care. Our five reportable segments are comprised of: • Beauty : Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin Care); • Grooming : Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming); • Health Care : Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Other Personal Health Care); • Fabric & Home Care : Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional, Surface Care); and • Baby, Feminine & Family Care : Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care (Paper Towels, Tissues, Toilet Paper). Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are as follows: % of Net sales by operating segment (1) Three Months Ended September 30 2023 2022 Fabric Care 23 % 23 % Home Care 12 % 12 % Skin and Personal Care 10 % 10 % Baby Care 9 % 10 % Hair Care 9 % 9 % Family Care 8 % 8 % Grooming 8 % 8 % Oral Care 8 % 8 % Feminine Care 7 % 6 % Personal Health Care 6 % 6 % Total 100 % 100 % (1) % of Net sales by operating segment excludes sales recorded in Corporate. The following is a summary of reportable segment results: Three Months Ended September 30 Net Sales Earnings/(Loss) Before Income Taxes Net Earnings/(Loss) Beauty 2023 $ 4,097 $ 1,249 $ 971 2022 3,961 1,271 1,011 Grooming 2023 1,724 533 421 2022 1,625 503 404 Health Care 2023 3,074 889 689 2022 2,757 800 617 Fabric & Home Care 2023 7,646 2,031 1,569 2022 7,082 1,543 1,172 Baby, Feminine & Family Care 2023 5,186 1,408 1,075 2022 4,934 1,055 805 Corporate 2023 144 (308) (168) 2022 253 (175) (46) Total Company 2023 $ 21,871 $ 5,802 $ 4,556 2022 20,612 4,997 3,963

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Goodwill and Intangible Assets Goodwill is allocated by reportable segment as follows: Beauty Grooming Health Care Fabric & Home Care Baby, Feminine & Family Care Total Company Goodwill at June 30, 2023 $ 13,888 $ 12,703 $ 7,718 $ 1,821 $ 4,529 $ 40,659 Acquisitions and divestitures — — — — — — Translation and other (152) (109) (100) (14) (44) (420) Goodwill at September 30, 2023 $ 13,736 $ 12,594 $ 7,618 $ 1,807 $ 4,485 $ 40,239 Goodwill decreased from June 30, 2023, primarily due to currency translation. Identifiable intangible assets at September 30, 2023, were comprised of: Gross Carrying Amount Accumulated Amortization Intangible assets with determinable lives $ 8,990 $ (6,308) Intangible assets with indefinite lives 20,955 — Total identifiable intangible assets $ 29,945 $ (6,308) Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended September 30, 2023 and 2022, was $87 and $80, respectively. Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. If the resulting fair value is less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets occurs during the three months ended December 31. Most of our goodwill reporting units have fair value cushions that significantly exceed their underlying carrying values. The Gillette indefinite-lived intangible asset is most susceptible to future impairment risk. Based on our latest annual impairment testing performed during the three months ended December 31, 2022, the Gillette indefinite-lived intangible asset's fair value exceeded its carrying value by approximately 5%. As of September 30, 2023, the carrying value of the Gillette indefinite-lived intangible asset was $14.1 billion. We concluded that no triggering event has occurred during the quarter ended September 30, 2023. Adverse changes in the business or in the macroeconomic environment, including foreign currency devaluation, increasing global inflation, market contraction from an economic recession and the Russia-Ukraine War, could reduce the underlying cash flows used to estimate the fair value of the Gillette indefinite-lived intangible asset and trigger a future impairment charge. Further reduction of the Gillette business activities in Russia could reduce the estimated fair value by up to 5%. The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales growth rates (including residual growth rates), discount rate and royalty rates. Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors, including the Russia-Ukraine War, could result in additional and prolonged devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which the Gillette brand is expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are consistent with the brand operating plans and approximate expected long-term category market growth rates. The residual growth rate depends on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased competitive environment. The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S. The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins. We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended December 31, 2022, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rates to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rates, which may result in an impairment of the Gillette indefinite-lived intangible asset. Approximate Percent Change in Estimated Fair Value +25 bps Discount Rate -25 bps Growth Rates -50 bps Royalty Rate Gillette indefinite-lived intangible asset (6) % (6) % (4) %

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Earnings Per Share Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of stock options and other share-based awards based on the treasury stock method and the assumed conversion of preferred stock. Net earnings per common share were calculated as follows: CONSOLIDATED AMOUNTS Three Months Ended September 30 2023 2022 Net earnings $ 4,556 $ 3,963 Less: Net earnings attributable to noncontrolling interests 35 24 Net earnings attributable to P&G (Diluted) 4,521 3,939 Less: Preferred dividends 70 71 Net earnings attributable to P&G available to common shareholders (Basic) $ 4,450 $ 3,868 SHARES IN MILLIONS Basic weighted average common shares outstanding 2,360.0 2,385.5 Add: Effect of dilutive securities Convertible preferred shares (1) 74.6 77.4 Stock options and other unvested equity awards (2) 40.6 40.7 Diluted weighted average common shares outstanding 2,475.2 2,503.6 NET EARNINGS PER COMMON SHARE (3) Basic $ 1.89 $ 1.62 Diluted $ 1.83 $ 1.57 (1) An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. (2) Excludes approximately 1 million and 18 million for the three months ended September 30, 2023 and 2022, respectively of weighted average stock options outstanding because the exercise price of these options was greater than their average market value or their effect was antidilutive. (3) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

SHARE-BASED COMPENSATION AND PO

SHARE-BASED COMPENSATION AND POSTRETIREMENT BENEFITS	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Compensation and Employee Benefit Plans [Text Block]	Share-Based Compensation and Postretirement Benefits The following table provides a summary of our share-based compensation expense and postretirement benefit impacts: Three Months Ended September 30 2023 2022 Share-based compensation expense $ 125 $ 105 Net periodic benefit cost for pension benefits 57 43 Net periodic benefit credit for other retiree benefits (156) (132)

RISK MANAGEMENT ACTIVITIES AND

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Sep. 30, 2023
Risk Management Activities and Fair Value Measurements [Abstract]
Risk Management And Fair Value [Text Block]	Risk Management Activities and Fair Value Measurements As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and commodity prices. There have been no significant changes in our risk management policies or activities during the three months ended September 30, 2023. The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. There were no significant assets or liabilities that were remeasured at fair value on a non-recurring basis during the periods presented. Cash equivalents were $8.1 billion and $6.8 billion as of September 30, 2023 and June 30, 2023, respectively, and are classified as Level 1 within the fair value hierarchy. The Company had no other material investments in debt or equity securities during the periods presented. The fair value of long-term debt was $25.1 billion and $26.9 billion as of September 30, 2023 and June 30, 2023, respectively. This includes the current portion of long-term debt instruments ($3.0 billion and $3.9 billion as of September 30, 2023 and June 30, 2023, respectively). Certain long-term debt (debt designated as a fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments. Disclosures about Financial Instruments The notional amounts and fair values of financial instruments used in hedging transactions as of September 30, 2023 and June 30, 2023, are as follows: Notional Amount Fair Value Asset Fair Value (Liability) September 30, 2023 June 30, 2023 September 30, 2023 June 30, 2023 September 30, 2023 June 30, 2023 DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS Interest rate contracts $ 2,961 $ 4,044 $ — $ — $ (434) $ (445) DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS Foreign currency interest rate contracts $ 13,207 $ 11,005 $ 211 $ 26 $ (230) $ (631) TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS $ 16,168 $ 15,049 $ 211 $ 26 $ (664) $ (1,076) DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS Foreign currency contracts $ 4,310 $ 3,489 $ 4 $ 7 $ (34) $ (42) TOTAL DERIVATIVES AT FAIR VALUE $ 20,478 $ 18,538 $ 216 $ 33 $ (698) $ (1,118) The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair value adjustment, was $2.5 billion and $3.6 billion as of September 30, 2023 and June 30, 2023, respectively. In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments, was $11.5 billion and $11.8 billion as of September 30, 2023 and June 30, 2023, respectively. The increase in the derivative instruments designated as net investment hedges is primarily driven by the Company's decision to leverage favorable interest rate spreads in the foreign currency swap market. Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value hierarchy. Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a net liability position was $513 and $1,088 as of September 30, 2023 and June 30, 2023, respectively. The Company has not been required to post collateral as a result of these contractual features. Before tax gains on our financial instruments in hedging relationships are categorized as follows: Amount of Gain Recognized in OCI on Derivatives Three Months Ended September 30 2023 2022 DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS (1) (2) Foreign exchange contracts $ 285 $ 708 (1) For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $67 and $46 for the three months ended September 30, 2023 and 2022, respectively. (2) In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $344 and $698 for the three months ended September 30, 2023 and 2022, respectively. Amount of Gain/(Loss) Recognized in Earnings Three Months Ended September 30 2023 2022 DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS Interest rate contracts $ 11 $ (131) DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS Foreign currency contracts $ (71) $ (146)

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	3 Months Ended
	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Accumulated Other Comprehensive Income/(Loss) The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the reclassifications out of AOCI by component: Investment Securities Postretirement Benefit Plans Foreign Currency Translation Total AOCI Balance at June 30, 2023 $ 13 $ 67 $ (12,300) $ (12,220) OCI before reclassifications (1) (1) 44 (409) (367) Amounts reclassified to the Consolidated Statement of Earnings (2) — 1 — 1 Net current period OCI (1) 45 (409) (366) Less: OCI attributable to noncontrolling interests — — (2) (2) Balance at September 30, 2023 $ 11 $ 112 $ (12,707) $ (12,583) (1) Net of tax (benefit)/expense of $0, $22 and $148 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions. (2) Net of tax (benefit)/expense of $0, $(2) and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Postretirement benefit plan amounts are reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic postretirement costs.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Litigation We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows. We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of environmental remediation will materially affect our financial position, results of operations or cash flows. Income Tax Uncertainties The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably estimate the timing and ultimate settlement amounts until the close of an audit. Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

SUPPLY CHAIN FINANCING

SUPPLY CHAIN FINANCING	3 Months Ended
	Sep. 30, 2023
Statement of Financial Position [Abstract]
Supplier Finance Program [Text Block]	Supplier Finance ProgramsThe Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a Supply Chain Finance program (“SCF”) with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate participating suppliers' ability to sell receivables from the Company to an SCF bank. These participating suppliers negotiate their sales of receivables arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the Company’s creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier’s decision to sell a receivable. Once a qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company’s obligations to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier’s decisions to finance amounts under these arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount due to suppliers participating in SCF and included in Accounts payable was approximately $5.7 billion as of September 30, 2023 and June 30, 2023, and $5.8 billion as of June 30, 2022.

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are as follows: % of Net sales by operating segment (1) Three Months Ended September 30 2023 2022 Fabric Care 23 % 23 % Home Care 12 % 12 % Skin and Personal Care 10 % 10 % Baby Care 9 % 10 % Hair Care 9 % 9 % Family Care 8 % 8 % Grooming 8 % 8 % Oral Care 8 % 8 % Feminine Care 7 % 6 % Personal Health Care 6 % 6 % Total 100 % 100 % (1) % of Net sales by operating segment excludes sales recorded in Corporate. The following is a summary of reportable segment results: Three Months Ended September 30 Net Sales Earnings/(Loss) Before Income Taxes Net Earnings/(Loss) Beauty 2023 $ 4,097 $ 1,249 $ 971 2022 3,961 1,271 1,011 Grooming 2023 1,724 533 421 2022 1,625 503 404 Health Care 2023 3,074 889 689 2022 2,757 800 617 Fabric & Home Care 2023 7,646 2,031 1,569 2022 7,082 1,543 1,172 Baby, Feminine & Family Care 2023 5,186 1,408 1,075 2022 4,934 1,055 805 Corporate 2023 144 (308) (168) 2022 253 (175) (46) Total Company 2023 $ 21,871 $ 5,802 $ 4,556 2022 20,612 4,997 3,963

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	Goodwill is allocated by reportable segment as follows: Beauty Grooming Health Care Fabric & Home Care Baby, Feminine & Family Care Total Company Goodwill at June 30, 2023 $ 13,888 $ 12,703 $ 7,718 $ 1,821 $ 4,529 $ 40,659 Acquisitions and divestitures — — — — — — Translation and other (152) (109) (100) (14) (44) (420) Goodwill at September 30, 2023 $ 13,736 $ 12,594 $ 7,618 $ 1,807 $ 4,485 $ 40,239
Schedule of Intangible Assets and Goodwill [Table Text Block]	Identifiable intangible assets at September 30, 2023, were comprised of: Gross Carrying Amount Accumulated Amortization Intangible assets with determinable lives $ 8,990 $ (6,308) Intangible assets with indefinite lives 20,955 — Total identifiable intangible assets $ 29,945 $ (6,308)
Schedule of Potential Impacts to Estimated Fair Values [Table Text Block]	The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rates, which may result in an impairment of the Gillette indefinite-lived intangible asset. Approximate Percent Change in Estimated Fair Value +25 bps Discount Rate -25 bps Growth Rates -50 bps Royalty Rate Gillette indefinite-lived intangible asset (6) % (6) % (4) %

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Net earnings per common share were calculated as follows: CONSOLIDATED AMOUNTS Three Months Ended September 30 2023 2022 Net earnings $ 4,556 $ 3,963 Less: Net earnings attributable to noncontrolling interests 35 24 Net earnings attributable to P&G (Diluted) 4,521 3,939 Less: Preferred dividends 70 71 Net earnings attributable to P&G available to common shareholders (Basic) $ 4,450 $ 3,868 SHARES IN MILLIONS Basic weighted average common shares outstanding 2,360.0 2,385.5 Add: Effect of dilutive securities Convertible preferred shares (1) 74.6 77.4 Stock options and other unvested equity awards (2) 40.6 40.7 Diluted weighted average common shares outstanding 2,475.2 2,503.6 NET EARNINGS PER COMMON SHARE (3) Basic $ 1.89 $ 1.62 Diluted $ 1.83 $ 1.57 (1) An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. (2) Excludes approximately 1 million and 18 million for the three months ended September 30, 2023 and 2022, respectively of weighted average stock options outstanding because the exercise price of these options was greater than their average market value or their effect was antidilutive. (3) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

SHARE-BASED COMPENSATION AND _2

SHARE-BASED COMPENSATION AND POSTRETIREMENT BENEFITS (Tables)	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Compensation and Employee Benefit Plans [Table Text Block]	The following table provides a summary of our share-based compensation expense and postretirement benefit impacts: Three Months Ended September 30 2023 2022 Share-based compensation expense $ 125 $ 105 Net periodic benefit cost for pension benefits 57 43 Net periodic benefit credit for other retiree benefits (156) (132)

RISK MANAGEMENT ACTIVITIES AN_2

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Sep. 30, 2023
Risk Management Activities and Fair Value Measurements [Abstract]
Schedule of Derivative Instruments [Table Text Block]	The notional amounts and fair values of financial instruments used in hedging transactions as of September 30, 2023 and June 30, 2023, are as follows: Notional Amount Fair Value Asset Fair Value (Liability) September 30, 2023 June 30, 2023 September 30, 2023 June 30, 2023 September 30, 2023 June 30, 2023 DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS Interest rate contracts $ 2,961 $ 4,044 $ — $ — $ (434) $ (445) DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS Foreign currency interest rate contracts $ 13,207 $ 11,005 $ 211 $ 26 $ (230) $ (631) TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS $ 16,168 $ 15,049 $ 211 $ 26 $ (664) $ (1,076) DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS Foreign currency contracts $ 4,310 $ 3,489 $ 4 $ 7 $ (34) $ (42) TOTAL DERIVATIVES AT FAIR VALUE $ 20,478 $ 18,538 $ 216 $ 33 $ (698) $ (1,118)
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	Before tax gains on our financial instruments in hedging relationships are categorized as follows: Amount of Gain Recognized in OCI on Derivatives Three Months Ended September 30 2023 2022 DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS (1) (2) Foreign exchange contracts $ 285 $ 708 (1) For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $67 and $46 for the three months ended September 30, 2023 and 2022, respectively.
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount of Gain/(Loss) Recognized in Earnings Three Months Ended September 30 2023 2022 DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS Interest rate contracts $ 11 $ (131) DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS Foreign currency contracts $ (71) $ (146)

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	3 Months Ended
	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the reclassifications out of AOCI by component: Investment Securities Postretirement Benefit Plans Foreign Currency Translation Total AOCI Balance at June 30, 2023 $ 13 $ 67 $ (12,300) $ (12,220) OCI before reclassifications (1) (1) 44 (409) (367) Amounts reclassified to the Consolidated Statement of Earnings (2) — 1 — 1 Net current period OCI (1) 45 (409) (366) Less: OCI attributable to noncontrolling interests — — (2) (2) Balance at September 30, 2023 $ 11 $ 112 $ (12,707) $ (12,583) (1) Net of tax (benefit)/expense of $0, $22 and $148 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions. (2) Net of tax (benefit)/expense of $0, $(2) and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively.

SEGMENT INFORMATION - SALES (De

SEGMENT INFORMATION - SALES (Details)		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	100%	100%
Fabric Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	23%	23%
Home Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	12%	12%
Skin and Personal Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	10%	10%
Baby Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	9%	10%
Hair Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	9%	9%
Family Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	8%	8%
Oral Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	8%	8%
Grooming
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	8%	8%
Feminine Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	7%	6%
Personal Health Care [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments - Percent of Sales by Business Unit	[1]	6%	6%
[1]% of Net sales by operating segment excludes sales recorded in Corporate.

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net Sales	$ 21,871	$ 20,612
Earnings/(Loss) from Continuing Operations Before Income Taxes	5,802	4,997
Net Earnings/(Loss) from Continuing Operations	4,556	3,963
Beauty
Segment Reporting Information [Line Items]
Net Sales	4,097	3,961
Earnings/(Loss) from Continuing Operations Before Income Taxes	1,249	1,271
Net Earnings/(Loss) from Continuing Operations	971	1,011
Grooming
Segment Reporting Information [Line Items]
Net Sales	1,724	1,625
Earnings/(Loss) from Continuing Operations Before Income Taxes	533	503
Net Earnings/(Loss) from Continuing Operations	421	404
Health Care
Segment Reporting Information [Line Items]
Net Sales	3,074	2,757
Earnings/(Loss) from Continuing Operations Before Income Taxes	889	800
Net Earnings/(Loss) from Continuing Operations	689	617
Fabric and Home Care
Segment Reporting Information [Line Items]
Net Sales	7,646	7,082
Earnings/(Loss) from Continuing Operations Before Income Taxes	2,031	1,543
Net Earnings/(Loss) from Continuing Operations	1,569	1,172
Baby, Feminine & Family Care
Segment Reporting Information [Line Items]
Net Sales	5,186	4,934
Earnings/(Loss) from Continuing Operations Before Income Taxes	1,408	1,055
Net Earnings/(Loss) from Continuing Operations	1,075	805
Corporate
Segment Reporting Information [Line Items]
Net Sales	144	253
Earnings/(Loss) from Continuing Operations Before Income Taxes	(308)	(175)
Net Earnings/(Loss) from Continuing Operations	$ (168)	$ (46)

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - CHANGE IN THE NET CARRYING AMOUNT OF GOODWILL BY GLOBAL BUSINESS UNIT (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill at June 30, 2023	$ 40,659
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(420)
Goodwill at September 30, 2023	40,239
Beauty
Goodwill [Roll Forward]
Goodwill at June 30, 2023	13,888
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(152)
Goodwill at September 30, 2023	13,736
Grooming
Goodwill [Roll Forward]
Goodwill at June 30, 2023	12,703
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(109)
Goodwill at September 30, 2023	12,594
Health Care
Goodwill [Roll Forward]
Goodwill at June 30, 2023	7,718
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(100)
Goodwill at September 30, 2023	7,618
Fabric & Home Care
Goodwill [Roll Forward]
Goodwill at June 30, 2023	1,821
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(14)
Goodwill at September 30, 2023	1,807
Baby, Feminine & Family Care
Goodwill [Roll Forward]
Goodwill at June 30, 2023	4,529
Goodwill, Acquisitions and Divestitures	0
Goodwill, Translation and Other	(44)
Goodwill at September 30, 2023	$ 4,485

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - IDENTIFIABLE INTANGIBLE ASSETS (Details) $ in Millions	Sep. 30, 2023 USD ($)
Schedule of Finite and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 29,945
Accumulated Amortization	(6,308)
Intangible Assets with Indefinite Lives
Schedule of Finite and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	20,955
Accumulated Amortization	0
Intangible Assets with Determinable Lives
Schedule of Finite and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,990
Accumulated Amortization	$ (6,308)

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - FAIR VALUE SENSITIVITY (Details) - Intangible Assets with Indefinite Lives - Gillette	Dec. 31, 2022
25 bps Increase Discount Rate [Member]
SCHEDULE OF POTENTIAL IMPACTS TO ESTIMATED FAIR VALUES [Line Items]
Percent Change in Estimated Fair Value	(6.00%)
25 bps Decrease Long-Term Growth [Member]
SCHEDULE OF POTENTIAL IMPACTS TO ESTIMATED FAIR VALUES [Line Items]
Percent Change in Estimated Fair Value	(6.00%)
50 bps Decrease Long-Term Royalty [Member]
SCHEDULE OF POTENTIAL IMPACTS TO ESTIMATED FAIR VALUES [Line Items]
Percent Change in Estimated Fair Value	(4.00%)

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Other Significant Noncash Transactions [Line Items]
Amortization of Intangible Assets	$ 87	$ 80
RUSSIAN FEDERATION
Other Significant Noncash Transactions [Line Items]
Percent Change in Estimated Fair Value			5%
Gillette
Other Significant Noncash Transactions [Line Items]
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount			5%
Gillette | Intangible Assets with Indefinite Lives
Other Significant Noncash Transactions [Line Items]
Intangible Assets, Net (Including Goodwill)	$ 14,100

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share Reconciliation [Abstract]
Net Earnings		$ 4,556	$ 3,963
Net Income (Loss) Attributable to Noncontrolling Interest		35	24
Net Earnings/(Loss) Attributable to P&G (Diluted)		4,521	3,939
Dividends, Preferred Stock		70	71
Net Earnings/(Loss) Attributable to P&G Available to Common Shareholders (Basic)		$ 4,450	$ 3,868
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic Weighted Average Common Shares Outstanding		2,360	2,385.5
Effect of Dilutive Securities
Conversion of Preferred Shares	[1]	74.6	77.4
Exercise of Stock Options and Other Unvested Equity Awards	[2]	40.6	40.7
Diluted Weighted Average Common Shares Outstanding		2,475.2	2,503.6
Basic Net Earnings/(Loss) Per Common Share	[3],[4]	$ 1.89	$ 1.62
Diluted Net Earnings/(Loss) Per Common Share	[3],[4]	$ 1.83	$ 1.57
[1]An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.[2]Excludes approximately 1 million and 18 million for the three months ended September 30, 2023 and 2022, respectively of weighted average stock options outstanding because the exercise price of these options was greater than their average market value or their effect was antidilutive.[3]Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.[4]Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

EARNINGS PER SHARE - ANTIDILUTI

EARNINGS PER SHARE - ANTIDILUTIVE SECURITIES (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1	18

SHARE-BASED COMPENSATION AND _3

SHARE-BASED COMPENSATION AND POSTRETIREMENT BENEFITS (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Share-based Payment Arrangement, Expense	$ 125	$ 105
Pension Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	57	43
Other Postretirement Benefit Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$ (156)	$ (132)

RISK MANAGEMENT ACTIVITIES AN_3

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS - DERIVATIVE INSTRUMENTS, EFFECT ON OTHER COMPREHENSIVE INCOME (LOSS) (Details) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount		$ 20,478		$ 18,538
Derivative Asset		216		33
Derivative Liability		(698)		(1,118)
Derivatives in Net Investment Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net		67	$ 46
Accumulated Other Comprehensive Income, Gain (Loss)		$ 344	$ 698
Derivatives in Net Investment Hedging Relationships | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Description of Location of Gain (Loss) on Net Investment Hedges in Financial Statements	[1],[2]	285	708
Derivative, Notional Amount		$ 13,207		11,005
Derivative Asset		211		26
Derivative Liability		(230)		(631)
Derivatives in Fair Value Hedging Relationships | Interest Rate Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount		2,961		4,044
Derivative Asset		0		0
Derivative Liability		(434)		(445)
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount		16,168		15,049
Derivative Asset		211		26
Derivative Liability		(664)		(1,076)
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount		4,310		3,489
Derivative Asset		4		7
Derivative Liability		$ (34)		$ (42)
[1]For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $67 and $46 for the three months ended September 30, 2023 and 2022, respectively.[2]In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $344 and $698 for the three months ended September 30, 2023 and 2022, respectively.

RISK MANAGEMENT ACTIVITIES AN_4

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS - DERIVATIVE INSTRUMENTS GAIN (LOSS) (Details)		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Derivatives in Net Investment Hedging Relationships | Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Description of Location of Gain (Loss) on Net Investment Hedges in Financial Statements	[1],[2]	285	708
[1]For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $67 and $46 for the three months ended September 30, 2023 and 2022, respectively.[2]In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $344 and $698 for the three months ended September 30, 2023 and 2022, respectively.

RISK MANAGEMENT ACTIVITIES AN_5

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Interest Rate Contracts | Derivatives in Fair Value Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 11	$ (131)
Foreign Currency Contract | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ (71)	$ (146)

RISK MANAGEMENT ACTIVITIES AN_6

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash Equivalents, at Carrying Value	$ 8,100	$ 6,800
Collateral Already Posted, Aggregate Fair Value	513	1,088
Derivatives in Fair Value Hedging Relationships | Underlying, Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Underlying Debt Obligation, Carrying Amt	2,500	3,600
Derivatives in Net Investment Hedging Relationships | Underlying, Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Underlying Debt Obligation, Carrying Amt	11,500	11,800
Long-term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Fair Value	25,100	26,900
Long Term Debt, Current Maturities Measured at Fair Value	$ 3,000	$ 3,900

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - CHANGES IN AOCI AND RECLASSIFICATION OUT OF AOCI (Details) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Accumulated Other Comprehensive Income/(Loss)		$ (12,583)		$ (12,220)
OCI before Reclassifications	[1]	(367)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	1
Other Comprehensive Income (Loss), Net of Tax		(366)	$ (627)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest		(2)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income/(Loss)		11		13
OCI before Reclassifications	[1]	(1)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	0
Other Comprehensive Income (Loss), Net of Tax		(1)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest		0
Other Comprehensive Income (Loss) before Reclassifications, Tax	[1]	0
Reclassification from AOCI, Current Period, Tax	[2]	0
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest
Accumulated Other Comprehensive Income/(Loss)		112		67
OCI before Reclassifications	[1]	44
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	1
Other Comprehensive Income (Loss), Net of Tax		45
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest		0
Other Comprehensive Income (Loss) before Reclassifications, Tax	[1]	22
Reclassification from AOCI, Current Period, Tax	[2]	(2)
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income/(Loss)		(12,707)		$ (12,300)
OCI before Reclassifications	[1]	(409)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	0
Other Comprehensive Income (Loss), Net of Tax		(409)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest		(2)
Other Comprehensive Income (Loss) before Reclassifications, Tax	[1]	148
Reclassification from AOCI, Current Period, Tax	[2]	$ 0
[1]Net of tax (benefit)/expense of $0, $22 and $148 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions.[2]Net of tax (benefit)/expense of $0, $(2) and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively.

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - ADDITIONAL INFORMATION (Details)	3 Months Ended
	Sep. 30, 2023 countries audit taxable_jurisdiction
Loss Contingencies [Line Items]
Number of Countries With On The Ground Operations | countries	70
Number of Taxable Jurisdictions | taxable_jurisdiction	150
Minimum
Loss Contingencies [Line Items]
Number of Audits Typically Underway	30
Maximum
Loss Contingencies [Line Items]
Number of Audits Typically Underway	40

SUPPLY CHAIN FINANCING - ADDITI

SUPPLY CHAIN FINANCING - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Supplier Finance Program [Line Items]
Supplier Finance Program, Obligation	$ 5,700	$ 5,700	$ 5,800